Abstract
Mutations of tumor suppressor protein p53 are present in almost about 50% of all cancers. It has been reported that the p53 mutations cause aggregation and subsequent loss of p53 function, leading to cancer progression. Here in this study we focus on the inhibitory effects of cationic osmolyte molecules acetylcholine chloride, and choline on an aggregation prone 10 amino acid p53 mutant peptide WRPILTIITL, and the corresponding wildtype peptide RRPILTIITL in vitro. The characterization tools used for this study include Thioflavin- T (ThT) induced fluorescence, transmission electron microscopy (TEM), congo red binding, turbidity, dynamic light scattering (DLS), and cell viability assays. The results show that acetylcholine chloride in micromolar concentrations significantly inhibit p53 mutant peptide aggregation in vitro, and could be promising candidate for p53 mutant/ misfolded protein aggregation inhibition.
Keywords: Aggregation, acetylcholine chloride, p53 peptide, osmolytes, cancer, inhibition.
Graphical Abstract
Protein & Peptide Letters
Title:Inhibition of p53 Mutant Peptide Aggregation In Vitro by Cationic Osmolyte Acetylcholine Chloride
Volume: 24 Issue: 4
Author(s): Zhaolin Chen and Mathumai Kanapathipillai
Affiliation:
Keywords: Aggregation, acetylcholine chloride, p53 peptide, osmolytes, cancer, inhibition.
Abstract: Mutations of tumor suppressor protein p53 are present in almost about 50% of all cancers. It has been reported that the p53 mutations cause aggregation and subsequent loss of p53 function, leading to cancer progression. Here in this study we focus on the inhibitory effects of cationic osmolyte molecules acetylcholine chloride, and choline on an aggregation prone 10 amino acid p53 mutant peptide WRPILTIITL, and the corresponding wildtype peptide RRPILTIITL in vitro. The characterization tools used for this study include Thioflavin- T (ThT) induced fluorescence, transmission electron microscopy (TEM), congo red binding, turbidity, dynamic light scattering (DLS), and cell viability assays. The results show that acetylcholine chloride in micromolar concentrations significantly inhibit p53 mutant peptide aggregation in vitro, and could be promising candidate for p53 mutant/ misfolded protein aggregation inhibition.
Export Options
About this article
Cite this article as:
Chen Zhaolin and Kanapathipillai Mathumai, Inhibition of p53 Mutant Peptide Aggregation In Vitro by Cationic Osmolyte Acetylcholine Chloride, Protein & Peptide Letters 2017; 24 (4) . https://dx.doi.org/10.2174/0929866524666170123142858
DOI https://dx.doi.org/10.2174/0929866524666170123142858 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resistance to Antiangiogenic: Focus on Mechanisms
Current Angiogenesis (Discontinued) Clinical Applications of <sup>18</sup>F-FDG PET/CT in Monitoring Anti-cancer Therapies
Current Pharmaceutical Biotechnology Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA Meet Our Editor
Current Gene Therapy Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy Pharmacophore Modeling, Docking and Molecular Dynamics Studies on Caspase-3 Activators Binding at β-Tubulin Site
Current Computer-Aided Drug Design MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies
Current Drug Delivery Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Editorial [ Hot Topic:Biology in Anticancer Treatment (Guest Editor: Bruno Vincenzi)]
Current Cancer Drug Targets Immune Checkpoint Inhibitors in AML-A New Frontier
Current Cancer Drug Targets Cancer Stem Cells: Current Status and Therapeutic Implications in Cancer Therapy-A New Paradigm
Current Stem Cell Research & Therapy Synthesis and Antitumor Activity of Novel N-Benzoyl-N'-substituted Pyrimidinyl (Thio)semicarbazide Derivatives
Letters in Drug Design & Discovery Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Mini-Reviews in Medicinal Chemistry Effects of Tea Polyphenols and their Polymers on MAPK Signaling Pathways in Cancer Research
Mini-Reviews in Medicinal Chemistry